Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

摘要

BACKGROUND:The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio 'end-game' strategy.METHODS:We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a?pentavalent vaccine?with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a?hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim?) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00?=?$Ch 666.26).RESULTS:The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme.CONCLUSIONS:The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.